Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibrompropamidine SCHEMBL29709297 | 1.00 | F2 (1.00) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL21083095 | 0.98 | F2 (0.97) | F2PLAUST14PRSS1 | |
| SCHEMBL597315 | 0.95 | F2 (0.90) | F2PLAUST14PRSS1 | |
| SCHEMBL14599538 | 0.95 | F2 (0.90) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL28086367 | 0.92 | F2 (0.85) | F2PLAUST14PRSS1 | |
| SCHEMBL16360744 | 0.89 | F2 (0.79) | F2PLAUST14PRSS1 | |
| SCHEMBL22824438 | 0.88 | F2 (0.78) | F2PLAUST14PRSS1 | |
| SCHEMBL1428334 | 0.88 | F2 (0.78) | F2PLAUST14PRSS1 | |
| SCHEMBL16450812 | 0.86 | F2 (0.75) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL2471251 | 0.85 | F2 (0.72) | F2PLAUST14PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1964 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20250346910-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | COMMENSE BIO INC (US) | 2025-11-13 | — | — | US | claimed |
| EP-4637829-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | Cellis Sp. z o.o. ([Ltd.] (PL) | 2025-10-29 | — | — | EP | claimed |
| EP-4587062-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | Cellis AG (CH) | 2025-07-23 | — | — | EP | claimed |
| CN-119907692-A | Isolated targeted delivery system for the treatment of gliomas | 塞尔丽思股份公司 | 2025-04-29 | — | — | CN | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-20250075182-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2025-03-06 | — | — | US | claimed |
| WO-2024133541-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF OVARIAN CANCER | CELLIS SP. Z O.O. [LTD.] (PL) | 2024-06-27 | — | — | WO | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| EP-3310904-B1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2024-04-03 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000030599-A1 | SKIN DEODORIZING AND SANITIZING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2000-06-02 | — | — | WO | claimed |
| EP-0617611-B1 | ORAL OSMOTIC DEVICE | ALZA CORP (US) | 1996-01-31 | — | — | EP | claimed |
| US-5357636-A | Flexible protective medical gloves and methods for their use | DRESDNER JR KARL P (US) | 1994-10-25 | — | — | US | claimed |
| EP-0439450-B1 | PHARMACEUTICAL COMPOSITION | SMITH & NEPHEW plc (GB) | 1992-12-23 | — | — | EP | claimed |
| EP-0439450-A1 | PHARMACEUTICAL COMPOSITION. | SMITH & NEPHEW ASS (GB) | 1991-08-07 | — | — | EP | claimed |
| WO-1989000850-A1 | PHARMACEUTICAL COMPOSITION | SMITH & NEPHEW PLC (GB) | 1989-02-09 | — | — | WO | claimed |
| WO-1984004456-A1 | IMPROVED COMPOSITIONS FOR TREATING INFECTED BURN WOUNDS | UNIV STRATHCLYDE (GB) | 1984-11-22 | — | — | WO | claimed |
| EP-0125858-A1 | Improved compositions for treating infected burn wounds | University of Strathclyde (GB) | 1984-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CD47, TFRC, L1CAM | F2 3181/4885PLAU 3740/4885ST14 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.